PLYMOUTH, Minn., Jan. 9 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq: EVVV), a global endovascular device company, today announced the appointment of Shawn McCormick as Sr. Vice President and Chief Financial Officer, effective January 19, 2009. Mr. McCormick succeeds Patrick Spangler, who has resigned as Sr. Vice President and Chief Financial Officer effective January 19, 2009.
Mr. McCormick brings more than 15 years of experience in the medical device industry to ev3. He most recently served as Vice President, Corporate Development at Medtronic, Inc. where he was responsible for leading Medtronic's worldwide business development activities and previously had served in key corporate and divisional financial leadership roles within the Medtronic organization.
"We are very pleased to have someone with Shawn's experience join the ev3 management team," said Robert Palmisano, President and Chief Executive Officer of ev3. "His proven track record in financial management and business development will add tremendous value as we continue to focus on expanding our position in the peripheral vascular and neurovascular markets and delivering increased shareholder value. I would also like to thank Pat Spangler for his many contributions to ev3 over the past three and a half years. We wish him success in his future endeavors."
Mr. McCormick joined Medtronic in July 1992 and held various finance
positions during his tenure. From May 2008 to January 2009, he served as Vice
President, Corporate Development of Medtronic, Inc. From July 2007 to May
2008, he served as Vice President, Corporate Technology and New Ventures of
Medtronic. From July 2002 to July 2007, he was Vice President, Finance for
Medtronic's Spinal, Biologics and Navigation business. Prior to that, Mr.
McCormick held various other positions with Medtronic, including Corporate
Development Director, Principal Corporate Development Associate, Manager,
Financial Analysis, Senior Financial Analyst and Senior Auditor. Prior to
joining Medtronic, he spent almost four years with the public accounting firm
KPMG Peat Marwick. Mr. McCormick earned his M.B.A. from the
About ev3 Inc.
Since its founding in 2000, ev3 has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of peripheral vascular and neurovascular diseases. ev3's products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. The company offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today -- peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, thrombectomy catheters and occlusion balloons. More information about the company and its products can be found at http://www.ev3.net.
ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S. and other countries.
|SOURCE ev3 Inc.|
Copyright©2009 PR Newswire.
All rights reserved